Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 53
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT01352273 | MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations | ||
| NCT01859026 | A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | ||
| NCT00833326 | A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer | ||
| NCT00828165 | A Safety Study of ARRY-300 in Healthy Subjects | ||
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | ||
| NCT00959127 | A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer | ||
| NCT02089230 | MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy | ||
| NCT01469130 | A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors | ||
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | ||
| NCT02225574 | An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) | ||
| NCT00650767 | A Study of ARRY-438162 in Patients With Rheumatoid Arthritis | ||
| NCT01556568 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy | ||
| NCT00650572 | A Study of ARRY-380 in Patients With Advanced HER2+ Cancer | ||
| NCT01921335 | ARRY-380 + Trastuzuamab for Breast w/ Brain Mets | ||
| NCT00462358 | A Study of ARRY-520 in Patients With Advanced Cancer | ||
| NCT01316822 | A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers | ||
| NCT01894672 | BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | ||
| NCT02041481 | MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer | ||
| NCT02510001 | MEK and MET Inhibition in Colorectal Cancer | ||
| NCT04005144 | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | ||
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | ||
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | ||
| NCT00916227 | A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome | ||
| NCT03158103 | A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | ||
| NCT01820364 | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma | ||
| NCT04292119 | Lorlatinib Combinations in Lung Cancer | ||
| NCT01449058 | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | ||
| NCT00859755 | A Safety Study of ARRY-403 in Patients With Type 2 Diabetes | ||
| NCT01496495 | A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes | ||
| NCT01349725 | A Safety Study of ARRY-502 in Healthy Subjects | ||
| NCT01649336 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | ||
| NCT03170206 | Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer | ||
| NCT00710736 | A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer | ||
| NCT00790049 | A Safety Study of ARRY-371797 in Healthy Subjects | ||
| NCT00278902 | A Study of ARRY-334543 in Patients With Advanced Cancer | ||
| NCT00637702 | A Study of ARRY-334543 in Patients With Advanced Cancer | ||
| NCT01248923 | A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | ||
| NCT02834364 | BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) | ||
| NCT00085787 | A Study of ARRY-142886 in Patients With Advanced Cancer | ||
| NCT03231306 | Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | ||
| NCT03843775 | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | ||
| NCT01363232 | Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | ||
| NCT01828034 | First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma | ||
| NCT00862524 | A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer | ||
| NCT02050815 | MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function | ||
| NCT04598009 | Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | ||
| NCT02278133 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | ||
| NCT00729209 | A Study of ARRY-371797 in Patients With Rheumatoid Arthritis | ||
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | ||
| NCT02384083 | Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients |
